Cholesterol efflux capacity: An introduction for clinicians

Area of Science:

• Cardiovascular Medicine
• Lipid Metabolism
• Biomarker Discovery

Background:

• Epidemiologic studies suggest an inverse correlation between high-density lipoprotein cholesterol (HDL-C) and cardiovascular disease (CVD).
• However, recent genetic and clinical studies have challenged the causal role of HDL-C levels in CVD.
• Serum cholesterol efflux capacity (CEC), a measure of HDL function, has emerged as a potential independent predictor of CVD risk.

Purpose of the Study:

• To review recent large clinical studies on serum cholesterol efflux capacity (CEC).
• To discuss important methodological considerations for measuring CEC.
• To evaluate the potential of CEC as a therapeutic target for cardiovascular disease.

Main Methods:

• Review of recent large-scale clinical studies investigating serum cholesterol efflux capacity (CEC).
• Analysis of the correlation between in vitro CEC measurements and cardiovascular disease prevalence/incidence.
• Examination of methodological aspects and reproducibility of CEC assays.

Main Results:

• Recent studies indicate a correlation between in vitro CEC and cardiovascular disease (CVD) prevalence and incidence.
• This correlation appears independent of high-density lipoprotein cholesterol (HDL-C) concentration.
• Current data suggest CEC may be a more robust marker of HDL function and CVD risk than HDL-C levels.

Conclusions:

• Cholesterol efflux capacity (CEC) is a key indicator of high-density lipoprotein (HDL) function.
• CEC shows potential as a cardiovascular disease biomarker, independent of HDL-C levels.
• Further research is needed to standardize CEC measurement and explore its therapeutic potential.